Target intelligence / Profile preview

Forkhead box protein L2 (FOXL2)

Target
FOXL2
Molecular classification
Transcription factor, DNA-binding protein, Forkhead box/winged helix family
01

Overview

Forkhead box protein L2 (FOXL2) is a forkhead/winged-helix DNA-binding transcription factor highly expressed in the ovary, pituitary, and eyelid muscle precursor tissues. FOXL2 is necessary for ovarian development, granulosa cell differentiation, and repression of testis-specific pathways in females. It modulates transcription of genes involved in steroidogenesis, apoptosis, and cell cycle control. Mutations in FOXL2 are associated with genetic syndromes such as BPES (with or without premature ovarian failure), sex reversal syndromes in animals, and a characteristic C134W alteration in adult granulosa cell tumors. FOXL2 cooperatively regulates TP53 and other cancer-relevant genes, affecting cell proliferation and apoptosis. It is conserved across mammals and vertebrates and is considered a master regulator of ovarian identity and granulosa cell fate.

Other names
FOXL2BPES1BPESPFRKPINTOPOF3Forkhead transcription factor FOXL2Forkhead box L2BPES1 (Blepharophimosis–ptosis–epicanthus inversus syndrome 1)
02

Mechanism of action

Not directly applicable as FOXL2 is not the target of marketed drugs. In adult granulosa cell tumors, FOXL2 status (especially C134W mutation) is used diagnostically or for understanding tumor biology.

03

Biological functions

Regulation of gene transcriptionOvarian differentiation and functionGranulosa cell differentiationSuppression of testis formation (via SOX9 repression)Cell proliferationApoptosisSteroidogenesisRegulation of fat and reactive oxygen species metabolism in the ovary
04

Disease associations

Blepharophimosis–ptosis–epicanthus inversus syndrome (BPES)Premature ovarian failure (POF)Adult granulosa cell tumorsEndometriosis
05

Safety considerations

Therapeutic manipulation of FOXL2 may risk disruption of ovarian function, sex determination, and cell survival/apoptosis. Off-target or germline genetic editing may cause BPES and POF, or sex reversal in model systems.
06

Interacting drugs

None are currently established as direct FOXL2-targeting drugs; research is ongoing for modulators in ovarian cancer and endocrine pathologies. Most clinical significance is through its mutation status rather than direct pharmacological targeting.
07

Biomarkers

FOXL2 C134W mutation (biomarker in adult granulosa cell tumors)

Beyond the preview

Go deeper on Forkhead box protein L2 (FOXL2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forkhead box protein L2 (FOXL2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call